Work

A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions

Year: 2018

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2018-99-118990

Authors: Juliana Velez Lujan, Michael Y. Choi, Chaja Jacobs, Colin McCarthy, Alaina Heinen, Carlos Amaya-Chanaga, Thomas J. Kipps, Januario E Castro

Institutions: University of California San Diego, Moores Cancer Center, Pharmacyclics (United States), Mayo Clinic, Mayo Clinic Hospital, Mayo Clinic Comprehensive Cancer Center (Arizona)

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4256526460

Cites:

Cited by:

Related to: 10